Immune Pharmaceuticals Inc (IMNPQ)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Daniel G. Teper
Employees:
7
550 SYLVAN AVENUE, SUITE 101, ENGLEWOOD CLIFFS, NJ 07632
201-464-2677

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas.

Data derived from most recent annual or quarterly report
Market Cap 98.627 Thousand Shares Outstanding49.313 Million Avg 30-day Volume 380.173 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.23
Price to Revenue0.0 Debt to Equity9.8955 EBITDA-16.345 Million
Price to Book Value9.6635 Operating Margin0.0 Enterprise Value16.393 Million
Current Ratio0.025 EPS Growth-0.074 Quick Ratio0.005
1 Yr BETA 1.694 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-79.36 Altman Z-Score-12.136 Free Cash Flow to Firm -11.614 Million
View SEC Filings from IMNPQ instead.

View recent insider trading info

Immune Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IMNPQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMNPQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2020-02-04 by FIORINO ANTHONY S.
  • 3: filed on 2018-11-20 by CLARK JOHN P
  • 4: filed on 2018-05-23 by FIORINO ANTHONY S.
  • 4: filed on 2018-05-18 by FIORINO ANTHONY S.
  • 4: filed on 2017-09-18 by FIORINO ANTHONY S.
  • 3: filed on 2017-09-18 by FIORINO ANTHONY S.
  • 4: filed on 2017-07-20 by MAZA ELLIOT M
  • 4: filed on 2017-02-03 by IMMUNE PHARMACEUTICALS INC
  • 3: filed on 2017-02-03 by IMMUNE PHARMACEUTICALS INC
  • 4: filed on 2017-01-27 by IMMUNE PHARMACEUTICALS INC

    • Events (8k)

  • 8-K: filed on 2021-04-13:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2021-04-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2019-03-08:
    Item 1.03: Bankruptcy or Receivership
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2019-02-14:
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-12-19:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
  • 8-K: filed on 2018-12-06:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-11-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-11-26:
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
  • 8-K: filed on 2018-10-22:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2018-10-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FIORINO ANTHONY S.

    • Director
    		 0 2020-02-03 0

    CLARK JOHN P SEE REMARKS

    • Officer
    		 0 2018-11-13 0

    MAZA ELLIOT M INTERIM CEO

    • Officer
    • Director
    		 0 2017-07-18 0

    KIMBALL RANCH C

    • Director
    		 0 2017-01-26 0

    DURRANT CAMERON

    • Director
    		 0 2017-01-25 0

    KAZADO DANIEL

    • Director
    		 0 2017-01-25 0

    PALEY JEFFREY

    • Director
    		 0 2017-01-25 0

    NECZESNY JOHN A.

    • Director
    		 0 2017-01-25 0

    TEPER DANIEL GEDEON CEO

    • Officer
    • Director
    • 10% Owner
    		 5,865,280 2016-10-06 0

    LUCHI MONICA E. EVP & CMO

    • Officer
    		 777,778 2016-08-04 0

    MILITELLO JOHN SEE REMARKS

    • Officer
    		 0 2016-06-01 0

    BEN-AMI MIRI SEE REMARKS

    • Officer
    		 0 2016-06-01 0

    AZRIA RENE PIERRE

    • Director
    		 50,000 2015-09-14 0

    BERDUGO GAD CFO & SVP

    • Officer
    		 0 2015-05-08 0

    LERER RENE

    • Director
    		 0 2015-01-08 0

    SIDRANSKY DAVID

    • Director
    		 21,699 2015-01-08 0

    STANCIC ANA

    • Director
    		 0 2015-01-08 0

    KOBRIN ISAAC

    • Director
    		 2,400 2014-06-23 0

    COOK ROBERT W. CFO AND SENIOR VP

    • Officer
    • Director
    		 0 2014-02-03 0

    ALBOUY PIERRE

    • Director
    		 0 2013-08-25 0

    DE KERGROHEN HERVE

    • Director
    		 0 2013-08-25 0

    SAVAGE ROBERT G.

    • Director
    		 475,300 2013-08-12 0

    DUNTON ALAN W

    • Director
    		 705,000 2013-08-12 0

    BROWNLIE KEITH L

    • Director
    		 360,000 2013-08-12 0

    ALLARD STEPHANE CHIEF MEDICAL OFFICER

    • Officer
    		 417,513 2012-12-27 0

    YETTER WAYNE P.

    • Director
    		 0 2012-06-21 0

    WALDHEIM GERHARD

    • Director
    		 0 2012-06-21 0

    SMYTH A. COLLIER

    • Director
    		 0 2012-06-21 0

    BHAGWAT DILEEP SENIOR VP - PHARMA. DEVEL.

    • Officer
    		 0 2011-01-18 0

    TALLEY JOHN V. PRESIDENT, CEO AND DIRECTOR

    • Officer
    • Director
    		 0 2011-01-18 0

    WIEDEMANN OLIVER SEE REMARKS

    • Officer
    		 0 2011-01-10 0

    JACKSON GUY C.

    • Director
    		 0 2010-06-03 0

    TYRRELL BERNARD R SENIOR VP - SALES & MARKETING

    • Officer
    		 0 2010-02-11 0

    CHEN MICHAEL VP-GLOBAL BUSINESS DEVELOPMENT

    • Officer
    		 0 2009-02-20 0

    TSENG BEN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2009-01-05 0

    CASPRITZ GERT

    • Director
    		 No longer subject to file 2008-12-31 0

    BEDARD JOHN F.

    • Director
    		 0 2008-06-30 0

    DAMASK MICHAEL C CHIEF MEDICAL OFFICER

    • Officer
    		 0 2006-07-17 0

    LOCKHART EARLE VP - CLINICAL & REG AFFAIRS

    • Officer
    		 28,125 2006-01-05 0

    ELEFANT DOV CONTROLLER - VP - FIN & ADMIN

    • Officer
    		 28,125 2006-01-05 0

    MCCLURG MICHAEL VP - BUS DVLPMNT - ONCOLOGY

    • Officer
    		 20,000 2006-01-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments